|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-13
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with moderately-to-severely active extrarenal SLE.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:BrunettaPaul GPG,
pubmed-author:GordonCarolineC,
pubmed-author:HsiehHsin-JuHJ,
pubmed-author:IsenbergDavid ADA,
pubmed-author:LatinisKevin MKM,
pubmed-author:MerrillJoan TJT,
pubmed-author:NeuweltC MichaelCM,
pubmed-author:OatesJames CJC,
pubmed-author:ShanahanJoseph CJC,
pubmed-author:UtsetTammy OTO,
pubmed-author:WallaceDaniel JDJ,
pubmed-author:ZhangDavidD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
222-33
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20039413-Adult,
pubmed-meshheading:20039413-Antibodies, Monoclonal,
pubmed-meshheading:20039413-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20039413-B-Lymphocytes,
pubmed-meshheading:20039413-Double-Blind Method,
pubmed-meshheading:20039413-Female,
pubmed-meshheading:20039413-Humans,
pubmed-meshheading:20039413-Immunologic Factors,
pubmed-meshheading:20039413-Lupus Erythematosus, Systemic,
pubmed-meshheading:20039413-Male,
pubmed-meshheading:20039413-Quality of Life,
pubmed-meshheading:20039413-Severity of Illness Index,
pubmed-meshheading:20039413-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
|
|
pubmed:affiliation |
Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA. JTMmail@aol.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase III
|
